Eloxx Pharmaceuticals, Inc. Net Assets
Eloxx Pharmaceuticals, Inc. net assets. Based on the latest financial reports, Eloxx Pharmaceuticals, Inc. (ELOX) has net assets worth $46.42 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.39 Million) and total liabilities ($16.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ELOX net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $46.42 Million |
| % of Total Assets | 73.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | -153.19% |
| 10-Year Change | -361.08% |
| Growth Volatility | 180.32 |
Net Assets of Eloxx Pharmaceuticals, Inc. (2004–2025)
Net assets of Eloxx Pharmaceuticals, Inc. from 2004 to 2025. This chart illustrates how Eloxx Pharmaceuticals, Inc.'s net assets have evolved over time, based on quarterly financial data. See Eloxx Pharmaceuticals, Inc. net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Eloxx Pharmaceuticals, Inc. (2004–2025)
The table below shows the annual net assets of Eloxx Pharmaceuticals, Inc. from 2004 to 2025. For live market cap and overall valuation, see Eloxx Pharmaceuticals, Inc. (ELOX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-11.91 Million | +51.07% |
| 2024-12-31 | $-24.34 Million | -7.68% |
| 2023-12-31 | $-22.60 Million | -112.00% |
| 2022-12-31 | $-10.66 Million | -147.62% |
| 2021-12-31 | $22.38 Million | +118.81% |
| 2020-12-31 | $10.23 Million | -71.75% |
| 2019-12-31 | $36.21 Million | -15.61% |
| 2018-12-31 | $42.91 Million | +100.88% |
| 2017-12-31 | $21.36 Million | +368.38% |
| 2016-12-31 | $4.56 Million | -62.69% |
| 2015-12-31 | $12.22 Million | -55.53% |
| 2014-12-31 | $27.49 Million | +607.45% |
| 2013-12-31 | $3.89 Million | +9.37% |
| 2012-12-31 | $3.55 Million | -21.36% |
| 2011-12-31 | $4.52 Million | -43.40% |
| 2010-12-31 | $7.98 Million | +40.81% |
| 2009-12-31 | $5.67 Million | -42.37% |
| 2008-12-31 | $9.84 Million | +265.70% |
| 2007-12-31 | $2.69 Million | -8.89% |
| 2006-12-31 | $2.95 Million | -47.19% |
| 2005-12-31 | $5.59 Million | +18.15% |
| 2004-12-31 | $4.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eloxx Pharmaceuticals, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28800505900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Eloxx Pharmaceuticals, Inc. Net Assets Breakdown (December 2025)
Eloxx Pharmaceuticals, Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | % |
| Other Components | $288.62 Million | % |
| Total Equity | $-11.91 Million | 100.00% |
Eloxx Pharmaceuticals, Inc. Competitors by Market Cap
The table below lists competitors of Eloxx Pharmaceuticals, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mackolik Internet Hizmetleri Ticaret A.S.
IS:MACKO
|
$54.29 Million |
|
Li-FT Power Ltd.
F:WS0
|
$54.30 Million |
|
GrabAGun Digital Holdings Inc.
NYSE:PEW
|
$54.32 Million |
|
LUOYANG GLASS CO. H YC 1
F:LUG
|
$54.36 Million |
|
CHEET.M.ADR 50 NEW
F:0C9
|
$54.27 Million |
|
UIL Co. Ltd
KQ:049520
|
$54.26 Million |
|
Transat AT Inc
TO:TRZ
|
$54.24 Million |
|
TechPrecision Corporation Common stock
NASDAQ:TPCS
|
$54.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eloxx Pharmaceuticals, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -24,335,000 to -11,907,000, a change of 12,428,000.
- Net loss of 5,995,000 reduced equity.
- Other factors increased equity by 18,423,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.00 Million | -50.35% |
| Other Changes | $18.42 Million | +154.72% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Eloxx Pharmaceuticals, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $328539.93 | $13.45 | x |
| 2005-12-31 | $350015.72 | $13.45 | x |
| 2006-12-31 | $167916.15 | $13.45 | x |
| 2007-12-31 | $139934.39 | $13.45 | x |
| 2008-12-31 | $490068.71 | $13.45 | x |
| 2009-12-31 | $264111.56 | $13.45 | x |
| 2010-12-31 | $241264.33 | $13.45 | x |
| 2011-12-31 | $57335.49 | $13.45 | x |
| 2012-12-31 | $35455.67 | $13.45 | x |
| 2013-12-31 | $24383.76 | $13.45 | x |
| 2014-12-31 | $44171.17 | $13.45 | x |
| 2015-12-31 | $7463.24 | $13.45 | x |
| 2016-12-31 | $1975.17 | $13.45 | x |
| 2017-12-31 | $1888.85 | $13.45 | x |
| 2018-12-31 | $582.09 | $13.45 | x |
| 2019-12-31 | $418.61 | $13.45 | x |
| 2020-12-31 | $112.18 | $13.45 | x |
| 2021-12-31 | $140.77 | $13.45 | x |
| 2022-12-31 | $-54.13 | $13.45 | x |
| 2023-12-31 | $-96.70 | $13.45 | x |
| 2024-12-31 | $-71.22 | $13.45 | x |
| 2025-12-31 | $-10.61 | $13.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eloxx Pharmaceuticals, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-112.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -65.07% | -18469.32% | 0.00x | 1.10x | $-3.55 Million |
| 2005 | -53.29% | -2383.13% | 0.02x | 1.09x | $-3.54 Million |
| 2006 | -112.29% | -4972.38% | 0.02x | 1.20x | $-3.61 Million |
| 2007 | -120.90% | -1083.90% | 0.09x | 1.24x | $-3.52 Million |
| 2008 | -46.78% | -1007.62% | 0.04x | 1.08x | $-5.59 Million |
| 2009 | -101.04% | -2082.50% | 0.04x | 1.26x | $-6.29 Million |
| 2010 | -167.69% | -9559.65% | 0.01x | 1.74x | $-14.18 Million |
| 2011 | -160.91% | 0.00% | 0.00x | 1.90x | $-7.72 Million |
| 2012 | -146.72% | -2533.07% | 0.03x | 2.01x | $-5.41 Million |
| 2013 | -161.71% | 0.00% | 0.00x | 1.87x | $-6.50 Million |
| 2014 | -33.56% | -9225.23% | 0.00x | 1.21x | $-11.97 Million |
| 2015 | -147.76% | -24085.05% | 0.00x | 1.60x | $-19.29 Million |
| 2016 | -181.29% | -11023.91% | 0.01x | 2.02x | $-8.72 Million |
| 2017 | -99.31% | 0.00% | 0.00x | 1.16x | $-23.35 Million |
| 2018 | -109.96% | 0.00% | 0.00x | 1.18x | $-51.48 Million |
| 2019 | -140.49% | 0.00% | 0.00x | 1.63x | $-54.50 Million |
| 2020 | -338.00% | 0.00% | 0.00x | 2.59x | $-35.60 Million |
| 2021 | -298.10% | 0.00% | 0.00x | 2.02x | $-68.97 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.00 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.79 Million |
| 2024 | 0.00% | -49.43% | 2.14x | 0.00x | $-709.50K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.80 Million |
Industry Comparison
This section compares Eloxx Pharmaceuticals, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | $46.42 Million | -65.07% | 0.37x | $54.29 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney dis… Read more